ClinicalTrials.gg
CompletedNCT05478174Updated Oct 10, 2025Results posted

Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

A Phase 3 interventional study of HSK3486 and Propofol in General Anesthesia, sponsored by Haisco-USA Pharmaceuticals, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-10.

Sponsored by Haisco-USA Pharmaceuticals, Inc. (part of Haisco Pharmaceutical Group Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous [IV] slow injection over 30 [±5] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 [±5] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Read the detailed description

This is a multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery with endotracheal intubation.

After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 0.2 mg/kg dose over 10 [±2] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 [±5] seconds followed by an additional 1.0 mg/kg dose over 10 [±2]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (\<65 and ≥65 years), and Body Mass Index (BMI \<35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation [MOAA/S] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent.

Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used.

Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline [NS], lactated ringer's [LR], or 5% dextrose) will be administrated through IV infusion. Throughout the preinduction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.

02

Conditions studied

  • General Anesthesia
03

In context

Lead sponsor

Haisco-USA Pharmaceuticals, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Subjects undergoing elective surgery (non emergency, non cardiothoracic, and non intracranial surgery, anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.

    2. Males or females, aged ≥18 years old, with ASA-PS I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.

    3. ≥18 kg/m2. 4. Vital signs at screening: RR ≥10 and ≤24 breaths/min; SpO2≥92% in ambient air; SBP ≥90 and ≤160 mmHg; DBP ≥55 and ≤100 mmHg; HR ≥55 (or ≥50 if subjects are on beta blockers) and ≤100 beats/min.

    5. For all women of , negative serum pregnancy test at screening and must have negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential* must agree to use effective as defined in 7.3.4 from the time of consent until 30 days post study drug administration.

    6. Capable of understanding the procedures and methods of this study, willing to sign an Form, and able to complete this study in strict compliance with the study protocol.

    7. Willing to comply with the site's COVID guidelines and testing requirements as applicable.

    8. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) and no hospitalizations and urgent care for at least 1 year.

    *Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral salpingo-oophorectomy) or who are (defined 12 months since last regular menses).

Exclusion criteria

Exclusion criteria:

  1. to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
  2. Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
  3. Medical condition or evidence of increased sedation/general anesthesia risk as follows:

    1. Cardiovascular disorders: uncontrolled hypertension (SBP>160 mmHg and/or DBP >100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or corrected for HR using Fridericia's formula (QTcF)≥450ms for males and ≥470ms for females.
    2. History of severe obstructive lung disease (i.e., [FEV1] \<50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).
    3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.
    4. Patients with psychiatric diseases (schizophrenia, mania) who have not been on a stable treatment regimen (with SSRIs, SNRIs, TCAs, MAOIs) for at least 1 year or who have been hospitalized or had emergent/urgent care within the past year.
    5. Uncontrolled conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.
    6. Known glycosylated () greater than or equal to 10%.
    7. Known thyroid-stimulating hormone (TSH) value 10% outside the normal range or on thyroid replacement therapy with a known free T-4 level outside the normal range.
    8. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking >2 units (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).
    9. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.
  4. Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study as follows:

    1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.
    2. History (or family history) of malignant hyperthermia.
    3. Any previous failure of tracheal intubation.
    4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV [Appendix 7], neck mobility, short thyromental distance, and/or history of difficult intubation).
  5. Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids) taken within 5 half-lives prior to Day 1.
  6. Laboratory parameters measured at screening with the following levels:

    1. ≤1.5 x 109/L
    2. count \<80 x 109/L
    3. Hemoglobin \<90 g/L (without blood transfusion within 14 days)
    4. and/or aspartate transaminase ≥2.0 x (ULN)
    5. Total ≥2.0 x ULN
    6. Severe renal impairment defined by (CrCl) ≤30 mL/min
  7. Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
  8. Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
400 participants (actual)

Study arms

  • Experimental
    HSK3486

    HSK3486 for general anesthesia induction

    Drug: HSK3486

  • Active comparator
    Propofol

    Propofol for general anesthesia induction

    Drug: Propofol

Interventions

  • HSK3486 for induction of general anesthesia

  • Propofol for induction of general anesthesia.

    Also known as: Diprivan

06

What researchers measure

Primary outcomes

  1. Success Rate of General Anesthesia Induction

    1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

    Time frame: From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1 ( up to 5 minutes)

Secondary outcomes

  1. Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression

    The outcome is defined by all the following conditions: a) Desired depth of anesthesia for general elective surgery is defined if all following criteria are met: i) No clinical signs of inadequate depth of anesthesia, such as lacrimation, movement, vomiting, coughing, laryngospasm, bucking, swallowing reflex or bronchospasm etc. ii) No blood pressure (SBP, DBP, or MAP) increases more than 20% from baseline in response to any major operational procedures or noxious stimulus in defined period. iii) Subjects maintain desired depth of anesthesia for general elective surgery with BIS as an objective assessment (after reaching initial lowest value, BIS remains sustainable level at not more than 60). b) No significant respiratory depression, such as apnea, prior to the administration of rocuronium bromide. c) No significant cardiac depression indicated by blood pressure decrease that requires intervention, i.e., vasopressors and/or IV fluid resuscitation.

    Time frame: 15 minutes from end of drug administration

  2. Percentage of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1

    0 = No Pain 1-3 = Mild Pain 4-6 = Moderate Pain 7-9 = Severe Pain 10 = Worst pain imaginable

    Time frame: From start of drug administration to MOAA/S ≤1 (up to 3 minutes)

07

Results

Posted Oct 29, 2024

Participant flow

Participant flow — Overall Study
MilestoneHSK3486Propofol
Started267133
Dosed255129
Full analysis set255128
Safety set255129
Completed254129
Not completed134

Outcome measures

PrimarySuccess Rate of General Anesthesia Induction

1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

Time frame:
From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1 ( up to 5 minutes)
Reported as:
Count of participants · Participants
Success Rate of General Anesthesia Induction
ParticipantsHSK3486Propofol
Success Rate of General Anesthesia Induction253128
Statistical analysis
  • HSK3486 vs Propofol · Farrington-Manning method · p = <0.001 (P-Value for non inferiority test) · Risk difference (rd): -0.0078 · 95% CI -0.0411 to 0.0255
SecondaryPercentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression

The outcome is defined by all the following conditions: a) Desired depth of anesthesia for general elective surgery is defined if all following criteria are met: i) No clinical signs of inadequate depth of anesthesia, such as lacrimation, movement, vomiting, coughing, laryngospasm, bucking, swallowing reflex or bronchospasm etc. ii) No blood pressure (SBP, DBP, or MAP) increases more than 20% from baseline in response to any major operational procedures or noxious stimulus in defined period. iii) Subjects maintain desired depth of anesthesia for general elective surgery with BIS as an objective assessment (after reaching initial lowest value, BIS remains sustainable level at not more than 60). b) No significant respiratory depression, such as apnea, prior to the administration of rocuronium bromide. c) No significant cardiac depression indicated by blood pressure decrease that requires intervention, i.e., vasopressors and/or IV fluid resuscitation.

Time frame:
15 minutes from end of drug administration
Reported as:
Count of participants · Participants
Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression
ParticipantsHSK3486Propofol
Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression8853
Statistical analysis
  • HSK3486 vs Propofol · Cochran-Mantel-Haenszel · p = 0.171 · Risk difference (rd): -0.0716 · 95% CI -0.1742 to 0.0310
SecondaryPercentage of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1

0 = No Pain 1-3 = Mild Pain 4-6 = Moderate Pain 7-9 = Severe Pain 10 = Worst pain imaginable

Time frame:
From start of drug administration to MOAA/S ≤1 (up to 3 minutes)
Reported as:
Count of participants · Participants
Percentage of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1
ParticipantsHSK3486Propofol
Percentage of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥14258
Statistical analysis
  • HSK3486 vs Propofol · ANOVA · p = <0.001 · Mean difference (final values): -1.76 · 95% CI -2.22 to -1.31

Adverse events

Collected over Adverse Events (AEs) will be collected from the time of informed consent until the final study visit (Day 8). A treatment-emergent AE is defined as: an AE that occurs after the subject starts treatment with the IMP. If an Investigator becomes aware of a serious adverse event within 30 days after the last dose of study drug and it is considered by him/her to be caused by the study drug with a reasonable possibility, the event must be documented and reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HSK34860/255 (0%)6/255 (2.4%)178/255 (69.8%)
Propofol0/129 (0%)2/129 (1.6%)89/129 (69%)
Most frequent serious events
Most frequent serious events
EventHSK3486Propofol
Post-procedural hemorrhageInjury, poisoning and procedural complications2/2550/129
Ischemic strokeVascular disorders0/2551/129
Hiatus herniaGastrointestinal disorders0/2551/129
HypotensionVascular disorders1/2550/129
Confusional statePsychiatric disorders1/2550/129
Urinary tract infectionInfections and infestations1/2550/129
HypocalcemiaMetabolism and nutrition disorders1/2550/129
Most frequent other events
Showing 10 of 11
Most frequent other events
EventHSK3486Propofol
HypotensionVascular disorders52/25529/129
NauseaGastrointestinal disorders52/25525/129
Procedural PainInjury, poisoning and procedural complications38/25524/129
AstheniaGeneral disorders36/25523/129
Procedural HypotensionVascular disorders21/25517/129
HypertensionVascular disorders30/25515/129
VomittingGastrointestinal disorders16/2555/129
DizzinessNervous system disorders15/2556/129
HypoxiaRespiratory, thoracic and mediastinal disorders14/2556/129
ConstipationGastrointestinal disorders4/2557/129

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)HSK3486PropofolTotal
<=18 years000
Between 18 and 65 years19297289
>=65 years633194
Sex: Female, Male
Sex: Female, Male(Participants)HSK3486PropofolTotal
Female15384237
Male10244146
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HSK3486PropofolTotal
Hispanic or Latino341650
Not Hispanic or Latino220110330
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HSK3486PropofolTotal
American Indian or Alaska Native000
Asian707
Native Hawaiian or Other Pacific Islander011
Black or African American412061
White203102305
More than one race213
Unknown or Not Reported246
ASA-PS
ASA-PS(Participants)HSK3486PropofolTotal
ASA-PS I622789
ASA-PS II13574209
ASA-PS III582785
BMI
BMI(Participants)HSK3486PropofolTotal
<35kg/m^2204102306
≥35kg/m^2512677
08

Study locations

23 sites
  • Shoals Medical Trials, Inc.
    Sheffield, Alabama 35660, United States
  • Arizona Research Center
    Phoenix, Arizona 85053, United States
  • UC Davis Health
    Davis, California 95616, United States
  • Coastal Clinical Research Specialists
    Jacksonville, Florida 32250, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Gulfcoast Research Institute, Llc
    Sarasota, Florida 34232, United States
  • Phoenix Clinical Research
    Tamarac, Florida 33321, United States
  • ForCare Clinical Research
    Tampa, Florida 33613, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • NextStage Clinical Research - Abay Neuroscience Center
    Wichita, Kansas 67226, United States
  • Chesapeake Research Group, Llc
    Pasadena, Maryland 21122, United States
  • Brigham & Women'S Hospital
    Boston, Massachusetts 02115, United States
  • Duke University Health
    Durham, North Carolina 27710, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • HD Research
    Bellaire, Texas 77401, United States
  • Hd Research Llc.
    Carrollton, Texas 75006, United States
  • The University of Texas - MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Urology San Antonio Research
    San Antonio, Texas 78229, United States
  • Endeavor Clinical Trials
    San Antonio, Texas 78240, United States
  • Jbr Clinical Research
    Salt Lake City, Utah 84107, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Nov 2023, 15 months.

Results were first posted in Oct 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2022
First posted
Jul 28, 2022
StartActual
Jul 26, 2022
Primary completionActual
Nov 7, 2023
CompletionActual
Nov 14, 2023
Results first posted
Oct 29, 2024
Last update
Oct 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05478174
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Jul 26, 2022
Primary completion
Nov 7, 2023
Completion
Nov 14, 2023
Results posted
Oct 29, 2024
Last update
Oct 10, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion